The present invention provides a new Pictet-Spengler process useful for preparing tetrahydro-beta-carboline compounds.
本发明提供了一种新的皮克特-斯宾格勒过程,用于制备四氢-β-咔啉化合物。
Method for treating 5HT.sub.2B receptor related conditions
申请人:Eli Lilly and Company
公开号:US05688807A1
公开(公告)日:1997-11-18
The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.
[EN] METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS<br/>[FR] METHODE DE TRAITEMENT D'ETATS ASSOCIES AU RECEPTEUR 5HT2B
申请人:ELI LILLY AND COMPANY
公开号:WO1995024200A1
公开(公告)日:1995-09-14
(EN) The present invention provides methods for binding a 5-HT2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT2B related conditions. Finally, the invention provides an article of manufacture.(FR) L'invention concerne des méthodes de fixation du récepteur 5-HT2B chez les mammifères au moyen de composés connus et nouveaux, ainsi qu'une méthode de traitement ou de prévention d'états associés à 5-HT2B. Un article manufacturé est également décrit.
(EN) 本发明提供了一种使用已知和新颖化合物来结合哺乳动物中的5-HT2B受体的方法。此外,本发明还提供了一种用于治疗或预防5-HT2B相关疾病的方法。最后,本发明提供了一种制品。
(FR) La présente invention concerne des méthodes de fixation du récepteur 5-HT2B chez les mammifères au moyen de composés connus et nouveaux, ainsi qu'une méthode de traitement ou de prévention d'états associés à 5-HT2B. Un article manufacturé est également décrit.
Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor
申请人:Eli Lilly and Company
公开号:US05736544A1
公开(公告)日:1998-04-07
The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.
The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical:
wherein R
1
and R
2
are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R
3
represents a hydrogen atom or the like; and R
6
represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.